enGene Holdings Inc.
detalimogene voraplasmid
high-risk, non-muscle invasive bladder cancer (NMIBC)
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for detalimogene voraplasmid in high-risk, non-muscle invasive bladder cancer (NMIBC) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“The Company plans to provide an update in the second half of 2026.”